Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of SGN-PDL1V in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 5 more (2 arms), sponsored by Pfizer. Primary endpoints: Adverse Events, Laboratory abnormalities and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
SGN-PDL1V
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)triple-negative breast cancer (TNBC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05208762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208762.